Section Arrow
ASMB.NASDAQ
- Assembly Biosciences
Quotes are at least 15-min delayed:2025/12/31 19:01 EST
After Hours
Last
 35
+0.99 (+2.91%)
Bid
34.35
Ask
35
High 35.0025 
Low 33.35 
Volume 3.65K 
Regular Hours (Closed)
Last
 34.01
+1.88 (+5.85%)
Day High 
34.13 
Prev. Close
32.13 
1-M High
39.4743 
Volume 
91.42K 
Bid
34.35
Ask
35
Day Low
32 
Open
32.27 
1-M Low
31.51 
Market Cap 
508.20M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 33.57 
20-SMA 34.42 
50-SMA 33.71 
52-W High 39.705 
52-W Low 7.75 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.60/-2.47
Enterprise Value
510.83M
Balance Sheet
Book Value Per Share
11.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
28.52M
Operating Revenue Per Share
11.82
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
After Hours 0.3891 -0.0276 -6.62%
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
After Hours 0.4996 -1.0804 -68.38%
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
After Hours 8.83 +0.01 +0.11%
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
After Hours 3.93 +0.16 +4.24%
FBLGFibroBiologics0.2249-0.017-7.03%-- 
After Hours 0.232 +0.0071 +3.16%
Industry overview quotes are at least 15 minutes delayed
Business Description
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.